Progenity, Inc. (PROG)
Stock Price:
$8.96 USD
-0.14 (-1.54%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
404.67M |
| Revenue (ttm) |
113.31M |
| Net Income (ttm) |
n/a |
| Shares Out |
45.16M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$8.96 |
| Previous Close |
$9.10 |
| Change ($) |
-0.14 |
| Change (%) |
-1.54% |
| Day's Open |
9.07 |
| Day's Range |
8.80 - 9.07 |
| Day's Volume |
41,886 |
| 52-Week Range |
7.63 - 15.92 |
More Stats
| Market Cap |
404.67M |
| Enterprise Value |
465.67M |
| Earnings Date (est) |
Aug 13, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
45.16M |
| Float |
947,073 |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
485,325 |
| Short Ratio |
1.23 |
| Short % of Float |
3.72% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.57 |
| PB Ratio |
n/a |
| Revenue |
113.31M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
-61.00M |
| Net Cash / Share |
-1.35 |
| Gross Margin |
38.39% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
2 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.75*
(53.46% upside)
Low
11.0
Current: $8.96
High
17.0
Target: 13.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 144 | 128 |
| Revenue Growth | 12.51% | - |
| Gross Profit | 43.49 | 35.90 |
| Operating Income | -140 | -114 |
| Net Income | -148 | -129 |
| Shares Outstanding | 4.88 | 4.66 |
| Earnings Per Share | -46.87 | -27.72 |
| Operating Cash Flow | -106 | -65.13 |
| Capital Expenditures | -3.73 | -4.83 |
| Free Cash Flow | -110 | -69.96 |
| Cash & Equivalents | 33.04 | 69.21 |
| Total Debt | 73.37 | 72.74 |
| Net Cash / Debt | -40.33 | -3.53 |
| Assets | 102 | 116 |
| Liabilities | 186 | 153 |
| Book Value | -83.87 | -36.97 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Progenity, Inc. |
| Country |
United States |
| Employees |
676 |
| CEO |
Harry Stylli |
Stock Information
| Ticker Symbol |
PROG |
| Stock Exchange |
NASDAQ |
| Unique Identifier |
NASDAQ: PROG |
| IPO Date |
June 19, 2020 |
Description
Progenity, Inc., a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November, 2013. The company was incorporated in 2012 and is based in San Diego, California with a laboratory in Ann Arbor, Michigan. It has a bill payment location in Detroit, Michigan.